JP2023076596A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023076596A5 JP2023076596A5 JP2023060823A JP2023060823A JP2023076596A5 JP 2023076596 A5 JP2023076596 A5 JP 2023076596A5 JP 2023060823 A JP2023060823 A JP 2023060823A JP 2023060823 A JP2023060823 A JP 2023060823A JP 2023076596 A5 JP2023076596 A5 JP 2023076596A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 37
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 28
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 28
- 210000004027 cell Anatomy 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010069754 Acquired gene mutation Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 101001037136 Homo sapiens Immunoglobulin heavy variable 3-15 Proteins 0.000 claims 1
- 101001037140 Homo sapiens Immunoglobulin heavy variable 3-23 Proteins 0.000 claims 1
- 102100040220 Immunoglobulin heavy variable 3-23 Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 230000037439 somatic mutation Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2024576 | 2019-12-24 | ||
| NL2024576 | 2019-12-24 | ||
| PCT/NL2020/050813 WO2021133167A1 (en) | 2019-12-24 | 2020-12-22 | Tgf-beta-rii binding proteins |
| JP2022539245A JP7633259B2 (ja) | 2019-12-24 | 2020-12-22 | ＴＧＦ－βＲＩＩ結合タンパク質 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539245A Division JP7633259B2 (ja) | 2019-12-24 | 2020-12-22 | ＴＧＦ－βＲＩＩ結合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023076596A JP2023076596A (ja) | 2023-06-01 |
| JP2023076596A5 true JP2023076596A5 (enExample) | 2023-08-22 |
Family
ID=69700252
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539245A Active JP7633259B2 (ja) | 2019-12-24 | 2020-12-22 | ＴＧＦ－βＲＩＩ結合タンパク質 |
| JP2023060823A Pending JP2023076596A (ja) | 2019-12-24 | 2023-04-04 | ＴＧＦ－βＲＩＩ結合タンパク質 |
| JP2025018365A Pending JP2025083342A (ja) | 2019-12-24 | 2025-02-06 | ＴＧＦ－βＲＩＩ結合タンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539245A Active JP7633259B2 (ja) | 2019-12-24 | 2020-12-22 | ＴＧＦ－βＲＩＩ結合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025018365A Pending JP2025083342A (ja) | 2019-12-24 | 2025-02-06 | ＴＧＦ－βＲＩＩ結合タンパク質 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250270331A1 (enExample) |
| EP (2) | EP4081306A1 (enExample) |
| JP (3) | JP7633259B2 (enExample) |
| KR (2) | KR20230145542A (enExample) |
| CN (3) | CN115038497A (enExample) |
| AR (2) | AR120914A1 (enExample) |
| AU (2) | AU2020412201A1 (enExample) |
| BR (1) | BR112022012522A2 (enExample) |
| CA (1) | CA3165605A1 (enExample) |
| IL (2) | IL294181A (enExample) |
| MX (2) | MX2022007919A (enExample) |
| PH (1) | PH12022551527A1 (enExample) |
| TW (2) | TW202128747A (enExample) |
| WO (1) | WO2021133167A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024542879A (ja) * | 2021-11-19 | 2024-11-18 | メルス ナムローゼ フェンノートシャップ | Ｐｄ－１およびｔｇｆ－ｂｒｉｉ結合ドメインを含む多重特異性結合部位 |
| KR20250123916A (ko) | 2022-12-20 | 2025-08-18 | 메뤼스 엔.페. | FAP 결합 도메인 및 FAP와 TGF-βRII에 결합하는 이중특이성 결합 모이어티 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001206899A (ja) | 1999-11-18 | 2001-07-31 | Japan Tobacco Inc | ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途 |
| CN105884893A (zh) | 2002-07-18 | 2016-08-24 | 莫鲁斯有限公司 | 抗体混合物的重组生产 |
| PL3456190T3 (pl) | 2008-06-27 | 2022-06-06 | Merus N.V. | Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy |
| JO3096B1 (ar) | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| CA2823104A1 (en) | 2011-01-06 | 2012-07-12 | Glaxo Group Limited | Ligands that bind tgf-beta receptor ii |
| PL2900694T3 (pl) | 2012-09-27 | 2018-12-31 | Merus N.V. | Dwuswoiste przeciwciała igg jako aktywatory komórek t |
| EP3324996A4 (en) * | 2015-07-22 | 2019-04-17 | Scholar Rock, Inc. | GDF11 BINDING PROTEINS AND USES THEREOF |
| TW201825519A (zh) * | 2016-10-18 | 2018-07-16 | 美商美國禮來大藥廠 | TGFβ受體II抗體 |
| BR112020019795A2 (pt) | 2018-03-30 | 2021-01-05 | Merus N.V. | Anticorpo multivalente |
-
2020
- 2020-12-22 KR KR1020237034290A patent/KR20230145542A/ko active Pending
- 2020-12-22 US US17/757,953 patent/US20250270331A1/en active Pending
- 2020-12-22 CA CA3165605A patent/CA3165605A1/en active Pending
- 2020-12-22 WO PCT/NL2020/050813 patent/WO2021133167A1/en not_active Ceased
- 2020-12-22 EP EP20829233.4A patent/EP4081306A1/en active Pending
- 2020-12-22 BR BR112022012522A patent/BR112022012522A2/pt unknown
- 2020-12-22 CN CN202080094188.4A patent/CN115038497A/zh active Pending
- 2020-12-22 JP JP2022539245A patent/JP7633259B2/ja active Active
- 2020-12-22 AU AU2020412201A patent/AU2020412201A1/en active Pending
- 2020-12-22 EP EP23189839.6A patent/EP4269433A3/en active Pending
- 2020-12-22 PH PH1/2022/551527A patent/PH12022551527A1/en unknown
- 2020-12-22 CN CN202211726462.2A patent/CN116199780A/zh active Pending
- 2020-12-22 KR KR1020227023748A patent/KR20220117267A/ko active Pending
- 2020-12-22 IL IL294181A patent/IL294181A/en unknown
- 2020-12-22 CN CN202211726434.0A patent/CN116375869A/zh active Pending
- 2020-12-22 MX MX2022007919A patent/MX2022007919A/es unknown
- 2020-12-23 TW TW109145819A patent/TW202128747A/zh unknown
- 2020-12-23 AR ARP200103661A patent/AR120914A1/es unknown
- 2020-12-23 TW TW112150430A patent/TW202417513A/zh unknown
-
2022
- 2022-06-23 MX MX2024002182A patent/MX2024002182A/es unknown
-
2023
- 2023-02-13 AU AU2023200779A patent/AU2023200779A1/en active Pending
- 2023-04-04 JP JP2023060823A patent/JP2023076596A/ja active Pending
- 2023-07-09 IL IL304317A patent/IL304317A/en unknown
- 2023-11-07 AR ARP230102989A patent/AR130991A2/es unknown
-
2025
- 2025-02-06 JP JP2025018365A patent/JP2025083342A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11578131B2 (en) | Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules | |
| JP6697064B2 (ja) | ｐＨ範囲で結合性が異なる薬物動態改善のための抗ＴＦＰＩ抗体変異体 | |
| JP2020501531A5 (enExample) | ||
| CA2942546C (en) | Antibody-fynomer conjugates | |
| EP3105246B1 (en) | Targeted tgf beta inhibition | |
| ME02371B (me) | Sastojci i postupci za dijagnstikovanje i tretman raka | |
| JP2019532619A5 (enExample) | ||
| JP2020513809A5 (enExample) | ||
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| JP2018503365A5 (enExample) | ||
| AU2019224136A1 (en) | Use of a multimeric anti-DR5 binding molecule in combination with a chemotherapeutic agent for treating cancer | |
| CN110945027A (zh) | GARP-TGF-β抗体 | |
| JPWO2021139777A5 (enExample) | ||
| CA3173919A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer | |
| JP2023076596A5 (enExample) | ||
| IL268000B2 (en) | Cancer treatment with semphorin-4d antibody in combination with an epigenetic modulator factor | |
| CN114269782A (zh) | 抗tigit抗体及其应用 | |
| TW201825515A (zh) | Ｍｅｔ抗體以及其免疫結合物及用途 | |
| TW202124432A (zh) | 使用pd-1軸抑制劑及抗骨膜蛋白抗體治療癌症之方法 | |
| CN112996540B (zh) | 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途 | |
| JP2021531263A (ja) | 抗ヒトｐｄ−ｌ１抗体とその使用 | |
| JPWO2021190622A5 (enExample) | ||
| JPWO2021133167A5 (enExample) | ||
| RU2024126025A (ru) | Антитела против msln и способы их применения | |
| CN116724057A (zh) | 蛋白酶可切割的重组双特异性抗体和组合物及其用途 |